Edition:
India

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

149.71USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$149.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,238
52-wk High
$163.69
52-wk Low
$113.85

Select another date:

Thu, Dec 21 2017

BRIEF-Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)

* JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA

Pennsylvania man admits to trading on tips about drug company

Dec 15 A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

BRIEF-Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

* JAZZ PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DANIEL SWISHER AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Jazz Pharmaceuticals posts Q3 EPS of $1.03

* Jazz pharmaceuticals announces third quarter 2017 financial results

BRIEF-Jazz Pharma submits Vyxeo Marketing Authorization Application to European Medicines Agency

* Jazz Pharmaceuticals submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for treatment of certain types of high-risk acute myeloid leukemia Source text for Eikon: Further company coverage:

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​

BRIEF-Jazz Pharmac announces offering of $500 mln of exchangeable senior notes

* Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024

BRIEF-Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56

* Jazz Pharmaceuticals announces second quarter 2017 financial results

BRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos

* Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

BRIEF-Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement

* Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates

Select another date: